AGA Center for Diagnostics & Therapeutics

The mission of the AGA Center for Diagnostics and Therapeutics is to support the development of therapies and diagnostic tests that will enhance human health and improve the lives of patients with digestive disorders.

Work with Us

For more information on partnering with AGA, visit our new industry partner website at

Partner with AGA

Drug development is a complex, time-consuming and expensive process requiring the cooperation of various stakeholders. The AGA Center for Diagnostics and Therapeutics was created to provide objective, independent guidance to companies, regulators, investors and health-care professionals on the development of new therapies and diagnostics tests for digestive disorders.

Message from center chair

Colin W. Howden, MD, AGAF, chair of the center, shares background on how the center came to be and what you can expect from the center.


meeting recap

AGA Drug Development Conference

The center's first annual AGA Drug Development Conference focused on the challenges in treating upper GI tract disorders, including GERD, eosinophilic esophagitis, gastroparesis and functional dyspepsia

White Papers

The center has developed four white papers highlighting the current state and future directions in drug devlopment for upper GI disorders.

Introductory Editorial


Functional Dyspepsia



work with the center

The AGA Center for Diagnostics and Therapeutics is available to consult with pharmaceutical, biotech and diagnostics companies on the challenges they may face as they try to bring new drugs, biologics and diagnostics to market. The center is also interested in working with investigators developing new medicines or diagnostic tests for digestive disorders who may require guidance from thought leaders in the field. 

Scientific Advisory Board

The core of the center is a 12-person steering committee; members represent GI practice and research, large and small biopharmaceutical companies, and FDA.

This group reports to the AGA Institute Governing Board and will interact directly with FDA as necessary.


Colin W. Howden, MD, AGAF

Colin W. Howden, MD, AGAF (Chair)

Chief of Gastroenterology, University of Tennessee Health Science Center, Memphis, TN

J. SUmner Bell, III, MD, AGAF

J. Sumner Bell III, MD, AGAF

Gastroenterology, Ltd.,
Virginia Beach, VA

Donna Griebel, MD

Tara A. Altepeter, MD (FDA Liaison)

Food and Drug Administration,
Silver Spring, MD

M. Scott Harris, MD, AGAF

M. Scott Harris, MD, AGAF

Middleburg Consultants, Inc.,
Takoma Park, MD

Gary R. Lichtenstein, MD, AGAF

Gary R. Lichtenstein, MD, AGAF

Professor of Medicine; Director, Center
for Inflammatory Bowel Disease
Hospital of the University of Pennsylvania,
Philadelphia, PA

Loren Laine, MD, AGAF

Loren Laine, MD, AGAF

Professor of Medicine,
Yale University School of Medicine, Fairfield, CT

Nimish B. Vakil, MD, AGAF

Glenn T. Furuta, MD

Professor of Pediatrics; Lacache Chair
in Gastrointestinal Allergic & Imm. Diseases,
Children's Hospital Colorado,
Aurora, CO

Nimish B. Vakil, MD, AGAF

Fred Poordad, MD

Professor of Medicine
Texas Liver Institute/University of Texas Health Science Center,
San Antonio, TX

Rajeev Jain, MD, AGAFRajeev Jain, MD, AGAF (Governing Board Liaison)

Texas Digestive Disease Consultants,
Dallas, TX

Nimish B. Vakil, MD, AGAF

Nimish B. Vakil, MD, AGAF

Clinical Professor of Medicine, University of Wisconsin Medical School, Summit, WI

Debra G. Silberg, MD, PhD

Debra G. Silberg, MD, PhD

Vice President, Global Development, Shire Pharmaceuticals,
Elkins Park, PA

Teresa L. Wright, MD, AGAF

Teresa L. Wright, MD, AGAF

Clinical Development,
San Francisco, CA

AGA Staff Contact: Alison Kim

*Denotes non-voting member.